Otter Creek Advisors LLC Decreases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Otter Creek Advisors LLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 17.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,196 shares of the medical research company’s stock after selling 258 shares during the quarter. Otter Creek Advisors LLC’s holdings in IQVIA were worth $235,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. FMR LLC boosted its position in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in IQVIA in the third quarter valued at about $147,683,000. JPMorgan Chase & Co. boosted its holdings in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, KBC Group NV increased its holdings in shares of IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after acquiring an additional 250,458 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.1 %

IQV stock opened at $190.77 on Thursday. The stock has a market capitalization of $33.59 billion, a P/E ratio of 25.44, a P/E/G ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The firm has a 50-day simple moving average of $199.40 and a 200-day simple moving average of $215.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. Leerink Partners reiterated an “outperform” rating and set a $248.00 price objective (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Bank of America cut their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Truist Financial reaffirmed a “buy” rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Finally, Robert W. Baird cut their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $251.22.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.